|
Age at first symptoms (days)a
|
20 (9;33)
|
|
Hemodynamic instability
|
28 (42%)
|
|
Strains
|
|
Staphylococcus epidermidis
|
23 (35%)
|
|
Staphylococcus capitis
|
11 (17%)
|
|
Staphylococcus aureus
|
9 (14%)
|
|
Staphylococcus haemolyticus
|
3 (5%)
|
|
Enterobacter cloacae
|
1 (2%)
|
|
Staphylococcus gallinarum
|
1 (2%)
|
|
No identification (clinical sepsis)
|
7 (11%)
|
|
Polymicrobial
|
11 (17%)
|
|
Resistance to vancomycin
|
2 (3%)
|
|
Site of infection
|
|
All bacteremia
|
39 (59%)
|
|
Including persistent bacteremia
|
25 (64%)
|
|
Isolated bacteremia
|
32 (48%)
|
|
Pneumoniae
|
23 (35%)
|
|
Other (CSF, peritoneal fluid)
|
4 (6%)
|
|
No identification (clinical sepsis)
|
7 (11%)
|
|
First-line treatment
|
|
Vancomycin
|
51 (77%)
|
|
Linezolid
|
12 (18%)
|
|
Other
|
3 (5%)
|
|
Antibiotic association (≥ 2 antibiotics)
|
46 (70%)
|
|
including amikacin
|
43 (93%)
|
|
Delay before linezolid use (days)a
|
3 (2;6)
|
|
Linezolid treatment duration (days)a
|
7 (3;10)
|
|
Central line removal
|
25 (38%)
|
|
In case of persistent bacteremia
|
21 (88%)
|
